JP2017500320A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017500320A5 JP2017500320A5 JP2016540552A JP2016540552A JP2017500320A5 JP 2017500320 A5 JP2017500320 A5 JP 2017500320A5 JP 2016540552 A JP2016540552 A JP 2016540552A JP 2016540552 A JP2016540552 A JP 2016540552A JP 2017500320 A5 JP2017500320 A5 JP 2017500320A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- inhibitor
- cas number
- delta
- intellikine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361919625P | 2013-12-20 | 2013-12-20 | |
| US61/919,625 | 2013-12-20 | ||
| PCT/US2014/071724 WO2015095825A1 (en) | 2013-12-20 | 2014-12-19 | Cancer treatments using combinations of type 2 mek and erk inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017500320A JP2017500320A (ja) | 2017-01-05 |
| JP2017500320A5 true JP2017500320A5 (https=) | 2018-02-08 |
| JP6678583B2 JP6678583B2 (ja) | 2020-04-22 |
Family
ID=53403790
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016540552A Active JP6678583B2 (ja) | 2013-12-20 | 2014-12-19 | ２型ｍｅｋ阻害剤およびｅｒｋ阻害剤の組み合わせを用いるがん処置 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11007184B2 (https=) |
| EP (3) | EP3984537B1 (https=) |
| JP (1) | JP6678583B2 (https=) |
| AU (1) | AU2014368912B2 (https=) |
| ES (2) | ES2953311T3 (https=) |
| WO (1) | WO2015095825A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3613743B1 (en) | 2008-01-04 | 2022-03-16 | Intellikine, LLC | Processes for the preparation of 1h-pyrazolo[3,4-d]pyrimidin-4-amine derivatives |
| US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
| TWI674262B (zh) | 2011-01-10 | 2019-10-11 | 美商英菲尼提製藥股份有限公司 | 製備異喹啉酮之方法及異喹啉酮之固體形式 |
| US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
| EP2914296B2 (en) | 2012-11-01 | 2021-09-29 | Infinity Pharmaceuticals, Inc. | Treatment of cancers using pi3 kinase isoform modulators |
| WO2015160975A2 (en) | 2014-04-16 | 2015-10-22 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| RU2754507C2 (ru) | 2016-06-24 | 2021-09-02 | Инфинити Фармасьютикалз, Инк. | Комбинированная терапия |
| DK3506899T3 (da) * | 2016-08-31 | 2022-03-07 | Childrens Hospital Philadelphia | Præparater og fremgangsmåder til diagnosticering og behandling af lymfesystemlidelser |
| JP7341060B2 (ja) | 2017-02-10 | 2023-09-08 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | Ｍａｐｋ経路の活性化に関連付けられる癌の処置のための方法及び医薬組成物 |
| AU2018269982B2 (en) | 2017-05-16 | 2024-06-13 | Biomed Valley Discoveries, Inc. | Compositions and methods for treating cancer with atypical BRAF mutations |
| US11406605B2 (en) * | 2017-12-20 | 2022-08-09 | Golden Biotechnology Corporation | Therapeutic compositions for treating pancreatic cancer |
| WO2019139970A1 (en) * | 2018-01-09 | 2019-07-18 | Duke University | Topical administration of mek inhibiting agents for the treatment of skin disorders |
| JP7582694B2 (ja) | 2020-01-10 | 2024-11-13 | イミューニヤリング コーポレーション | Ｍｅｋ阻害剤及びその治療的使用 |
| US11066358B1 (en) * | 2021-02-17 | 2021-07-20 | Warner-Lambert Company Llc | Compositions of essentially pure form IV of N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof |
| US11084780B1 (en) | 2021-02-17 | 2021-08-10 | Springworks Therapeutics, Inc. | Crystalline solids of MEK inhibitor N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
| US5235033A (en) | 1985-03-15 | 1993-08-10 | Anti-Gene Development Group | Alpha-morpholino ribonucleoside derivatives and polymers thereof |
| ATE220114T1 (de) | 1993-03-19 | 2002-07-15 | Sequenom Inc | Dns-sequenzbestimmung durch massenspektrometrie auf dem weg des abbaus mit exonuklease |
| US6140053A (en) | 1996-11-06 | 2000-10-31 | Sequenom, Inc. | DNA sequencing by mass spectrometry via exonuclease degradation |
| US7601497B2 (en) | 2000-06-15 | 2009-10-13 | Qiagen Gaithersburg, Inc. | Detection of nucleic acids by target-specific hybrid capture method |
| US7439016B1 (en) | 2000-06-15 | 2008-10-21 | Digene Corporation | Detection of nucleic acids by type-specific hybrid capture method |
| GB0320059D0 (en) | 2003-08-27 | 2003-10-01 | Solexa Ltd | A method of sequencing |
| LT3305776T (lt) | 2004-05-14 | 2020-01-10 | Vertex Pharmaceuticals Incorporated | Pirolo junginiai kaip erk baltymo kinazės inhibitoriai, ir farmacinės kompozicijos su šiais junginiais |
| US7582623B2 (en) | 2004-05-20 | 2009-09-01 | The Regents Of The University Of California | Photoactive metal nitrosyls for blood pressure regulation and cancer therapy |
| US20060228721A1 (en) | 2005-04-12 | 2006-10-12 | Leamon John H | Methods for determining sequence variants using ultra-deep sequencing |
| TW200829234A (en) * | 2007-01-08 | 2008-07-16 | Golden Biotechnology Corp | Antrodia camphorata isophorone extract |
| AR068046A1 (es) * | 2007-06-05 | 2009-11-04 | Schering Corp | Derivados policiclicos de indazol y su uso como inhibidores de erk para el tratamiento del cancer |
| WO2010062546A1 (en) | 2008-10-27 | 2010-06-03 | Qiagen Gaithersburg Inc. | Fast results hybrid capture assay on an automated platform |
| KR20120046018A (ko) | 2010-10-04 | 2012-05-09 | 삼성테크윈 주식회사 | 단일 뉴클레오티드 다형성의 실시간 ｐｃｒ 검출 |
| WO2012068562A2 (en) * | 2010-11-19 | 2012-05-24 | The Regents Of The University Of California | Compositions and methods for detection and treatment of b-raf inhibitor-resistant melanomas |
| US20130004481A1 (en) * | 2011-01-12 | 2013-01-03 | Boehringer Ingelheim International Gmbh | Anticancer therapy |
| US20130023531A1 (en) * | 2011-01-27 | 2013-01-24 | Boehringer Ingelheim International Gmbh | Pyrimido[5,4-d]pyrimidylamino phenyl sulfonamides as serine/threonine kinase inhibitors |
| WO2012125848A2 (en) | 2011-03-16 | 2012-09-20 | Baylor College Of Medicine | A method for comprehensive sequence analysis using deep sequencing technology |
| US20150166646A1 (en) * | 2012-06-15 | 2015-06-18 | The Wistar Institute Of Anatomy And Biology | Methods and Compositions for Treating or Diagnosing Melanoma |
-
2014
- 2014-12-19 JP JP2016540552A patent/JP6678583B2/ja active Active
- 2014-12-19 EP EP21193832.9A patent/EP3984537B1/en active Active
- 2014-12-19 WO PCT/US2014/071724 patent/WO2015095825A1/en not_active Ceased
- 2014-12-19 AU AU2014368912A patent/AU2014368912B2/en active Active
- 2014-12-19 ES ES14871217T patent/ES2953311T3/es active Active
- 2014-12-19 EP EP14871217.7A patent/EP3082779B1/en active Active
- 2014-12-19 ES ES21193832T patent/ES2986019T3/es active Active
- 2014-12-19 US US15/105,871 patent/US11007184B2/en active Active
- 2014-12-19 EP EP24164571.2A patent/EP4389225A3/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017500320A5 (https=) | ||
| JP2017502017A5 (https=) | ||
| JP2017502013A5 (https=) | ||
| JP2017502016A5 (https=) | ||
| Leonard et al. | AUGMENT: a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma | |
| Tahara et al. | Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02) | |
| RU2016129287A (ru) | Лечение злокачественных опухолей с применением комбинаций ингибиторов erk и raf | |
| Galizia et al. | Cetuximab, a chimeric human mouse anti-epidermal growth factor receptor monoclonal antibody, in the treatment of human colorectal cancer | |
| JP7405408B2 (ja) | 異型ｂｒａｆ変異を有するがんを処置するための組成物および方法 | |
| Beuselinck et al. | Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases | |
| Budde et al. | Mosunetuzumab monotherapy is an effective and well-tolerated treatment option for patients with relapsed/refractory (R/R) follicular lymphoma (FL) who have received≥ 2 prior lines of therapy: pivotal results from a phase I/II study | |
| O’Sullivan | Overcoming endocrine resistance in hormone-receptor positive advanced breast cancer-the emerging role of CDK4/6 inhibitors | |
| JP2020519660A5 (https=) | ||
| JP2017502014A5 (https=) | ||
| Oudard et al. | Clinical activity of sunitinib rechallenge in metastatic renal cell carcinoma—Results of the REchallenge with SUnitinib in MEtastatic RCC (RESUME) Study | |
| CA2407466A1 (en) | Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype | |
| KR20140036193A (ko) | 아플리버셉트, 폴린산, 5-플루오로우라실(5-fu) 및 이리노세탄(folfiri)을 포함하는 조성물 | |
| Yoon et al. | Intracranial regression of an advanced basal cell carcinoma using sonidegib and itraconazole after failure with vismodegib | |
| CA2939464A1 (en) | Use of anti-ccr5 antibodies in graft versus host disease | |
| MX2014002471A (es) | Combinaciones sinergicas de los inhibidores de p13k y mek. | |
| Bracarda et al. | Could interferon still play a role in metastatic renal cell carcinoma? A randomized study of two schedules of sorafenib plus interferon-alpha 2a (RAPSODY) | |
| EP4520398A3 (en) | Treatment of prostate cancer | |
| JP2018519324A5 (https=) | ||
| Besse et al. | A phase Ib dose-escalation study of everolimus combined with cisplatin and etoposide as first-line therapy in patients with extensive-stage small-cell lung cancer | |
| Dummer et al. | Integrating first-line treatment options into clinical practice: what’s new in advanced melanoma? |